SHIELD THERAPEUTICS PLC
Commercializing a novel oral therapy for adults with iron deficiency.
STX | IL
Overview
Corporate Details
- ISIN(s):
- GB00BYV81293
- LEI:
- 213800G74QWY15FC3W71
- Country:
- United Kingdom
- Address:
- NORTHERN DESIGN CENTRE STUDIO 6, 3RD FLOOR, NE8 3DF GATESHEAD
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company focused on addressing the significant unmet medical need for patients with iron deficiency. The company's lead product is ACCRUFeR® (ferric maltol), a novel, stable, non-salt-based oral therapy for adults suffering from iron deficiency, with or without anemia. Shield Therapeutics is dedicated to the commercialization of its innovative treatments to improve the lives of patients across multiple therapeutic categories.
This is a Fraction of the Available Data.
You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for SHIELD THERAPEUTICS PLC and 9,000+ other companies.
Stop analyzing yesterday's news. Start building a real-time advantage.
Request Enterprise API AccessFilings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-09-15 08:00 |
Share Issue/Capital Change
£1.5 million placing supporting growth of ACCRUFeR
|
English | 18.2 KB | |
| 2025-08-27 08:13 |
Regulatory News Service
Data published -European Journal of Heart Failure
|
English | 21.9 KB | |
| 2025-08-21 13:06 |
Earnings Release
Interim results for the six months ended 30 Jun 25
|
English | 245.5 KB | |
| 2025-05-22 11:40 |
Annual Report
Shield Therapeutics plc 2024 Annual Report and Accounts
|
English | 4.4 MB | |
| 2025-04-22 08:01 |
Business and Financial Review
Licence Agreement in Japan for ACCRUFeR®
|
English | 22.9 KB | |
| 2025-03-11 08:00 |
Regulatory News Service
ACCRUFeR® launched in Canada
|
English | 21.0 KB | |
| 2025-02-13 17:15 |
Director's Dealing
PDMR Transaction Notification
|
English | 28.6 KB | |
| 2025-02-13 08:00 |
Remuneration Information
Grant of Share Options
|
English | 28.1 KB | |
| 2025-02-05 08:00 |
Earnings Release
Unaudited full year trading update
|
English | 22.4 KB | |
| 2025-01-27 08:00 |
Board/Management Information
Anders Lundstrom appointed CEO
|
English | 18.7 KB | |
| 2024-12-24 12:25 |
Post-Annual General Meeting Information
Result of General Meeting & Total Voting Rights
|
English | 27.9 KB | |
| 2024-12-23 08:00 |
Share Issue/Capital Change
Results of RetailBook Offer
|
English | 20.0 KB | |
| 2024-12-06 12:31 |
Share Issue/Capital Change
RetailBook Offer
|
English | 31.8 KB | |
| 2024-12-06 12:30 |
Share Issue/Capital Change
Subscription by AOP Health to raise US$10 million
|
English | 190.9 KB | |
| 2024-11-21 08:00 |
Regulatory News Service
Business Update
|
English | 21.1 KB |
Automate Your Workflow. Get a real-time feed of all SHIELD THERAPEUTICS PLC filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for SHIELD THERAPEUTICS PLC via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
